Krzysztof Reiss, PhD, earned his doctorate in cell biology from Jagiellonian University in Krakow, Poland, in 1989. At LSU, he is a Professor within the hematology/oncology section of the department of medicine and director of the SSSCC’s neurological cancer research program, which he co-founded with Luis Del Valle, MD.

Dr. Reiss’ research team focuses on molecular pathways involved in the development of cancer, particularly brain tumors. His laboratory investigates the roles of various proteins including growth factors, viral proteins, cell cycle regulators, and proteins associated with cell signaling and DNA repair in the development of brain tumors, including Glioblastomas, which are the most aggressive and incurable brain tumors, and Medulloblastomas, which are the most common brain tumors in children.

Research: Glioblastoma weak metabolic points as a target for new drugs with high potential for Blood-Brain Barrier penetration

Glioblastomas are the most aggressive and practically incurable brain neoplasms for which treatment options are very limited. The main obstacle preventing the development of more effective glioblastoma therapies is the Blood-Brain Barrier (BBB), which prevents the majority of anticancer drugs from penetrating intracranial tumor tissue at therapeutically
relevant concentrations. Our new anti-glioblastoma therapeutic approach is based on the previously reported anti-glioblastoma activity of the common lipid-lowering drug fenofibrate (FF).

He is also Principal Investigator of Center for Translational Viral Oncology (LSUHSC- New Orleans), Louisiana.

Center for Translational Viral Oncology (CTVO) – Krzysztof Reiss (grantome.com)

LSUHSC School of Medicine – Krzysztof Reiss, PhD